94619-73-5

Basic information

• Product Name: 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-4,5-dicyanoimidazole
• Synonyms: 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-4,5-dicyanoimidazole
• CAS NO: 94619-73-5
• Molecular Weight: 562.538
• Mol File: 94619-73-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-4,5-dicyanoimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-4,5-dicyanoimidazole(94619-73-5)
• EPA Substance Registry System: 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-4,5-dicyanoimidazole(94619-73-5)

Safety Data

• Hazardous Substances Data: 94619-73-5(Hazardous Substances Data)

Upstream product

• 1122-28-7 4,5-dicyano-1H-imidazole 
• 14215-97-5 1-O-acetyl-2,3,5-tri-O-benzoyl-D-ribofuranose 
• 6974-32-9 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose 
• 22224-38-0 1,2,3,5-tetra-O-benzoyl-β-D-ribofuranose 
• 94619-75-7 N-formyl-N'-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)diaminomaleonitrile 
• 94619-74-6 N-[(Z)-1,2-Dicyano-2-(trimethylsilanyl-amino)-vinyl]-formamide 
• 53144-01-7 N-((Z)-2-amino-1,2-dicyanoethenyl)formamide 
• 94619-71-3 N-(2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)diaminomaleonoitrile 
• 122-51-0 orthoformic acid triethyl ester 

Downstream Products

• 23192-64-5 5-amino-1-β-D-ribofuranosyl-1H-imidazole-4-carbonitrile 
• 2627-69-2 AICA riboside 

Relevant articles and documents

Purine nucleoside analogues for treating flaviviridae including hepatitis C

This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside whe

Ring-expanded nucleosides and nucleotides

The present invention relates to compositions comprising analogues of purine nucleotides containing a ring-expanded ("fat") heterocyclic ring, in place of purine, and an unmodified or modified sugar residue, pharmaceutically acceptable derivatives of such compositions, as well as methods of use thereof. In particular, these compositions may be utilized in the treatment of certain cancers, bacterial, fungal, parasitic and viral infections, including, but not limited to, Acquired Immunodeficiency Syndrome (AIDS) and hepatitis.

A short synthesis of a novel ring-expanded purine and its nucleoside analogue containing the imidazo[4,5-e][1,3]diazepine ring skeleton with multiple amino substituents attached to the 7-membered ring

The synthesis of 4,6,8-triaminoimidazo[4,5-e][1,3]diazepine (1) and its nucleoside analogue (6) are reported. The heterocycle was prepared in a single step by condensation of 4,5-dicyanoimidazole with guanidine. The 5,7- fused ring structure of 1 was distinguished from the other possible 5:5- fused isomer 2 by preparing the 15N-labeled heterocycle (1*) and exploring its 15N-1H coupling patterns in both 1H and 15N NMR spectra. These spectral patterns also enabled establishment of the triamino tautomeric form of 1 as assigned. Compound 1, a novel ring-expanded ('fat') analogue of purine, is anticipated to be planar and aromatic as predicted by molecular modeling. The 1-benzyl analogue (4), a protocol for the ribosyl analogue 6, was similarly prepared from 1-benzyl-4,5-dicyanoimidazole. The nucleoside 6 was prepared by the modified Vorbruggen ribosylation of 1. The position of ribosylation was unequivocally established by an unambiguous synthesis of 6 from condensation of 1-(2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)-4,5- dicyanoimidazole (7) with guanidine in a solution of sodium methoxide in methanol. The nucleoside 7 was prepared by the Vorbruggen ribosylation of 4,5-dicyanoimidazole.